Protara Therapeutics, Inc. (TARA) intrinsic value & 10-year financials
Protara Therapeutics, Inc. (TARA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.32
- Market cap
- $99.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -93.0%
- Free cash flow (FY2025)
- -$56.5M
TARA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$57.4M | -$1.34 | -$56.5M | — | -73.4% |
| FY2024 | — | -$44.6M | -$1.08 | -$35.9M | — | -218.0% |
| FY2023 | — | -$40.4M | -$1.78 | -$37.6M | — | -69.3% |
| FY2022 | — | -$66.0M | -$2.93 | -$26.6M | — | -61.1% |
| FY2021 | — | -$47.3M | -$2.10 | -$35.1M | — | -57.5% |
| FY2020 | — | -$34.0M | — | -$24.3M | — | -107.4% |
| FY2019 | — | -$15.0M | — | -$15.7M | — | -111.7% |
| FY2018 | — | -$20.7M | — | -$23.4M | — | -75.1% |
| FY2017 | — | -$30.0M | — | -$22.4M | — | -81.9% |
| FY2016 | — | -$28.5M | — | -$24.0M | — | -74.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Protara Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Protara Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -71.4% ROIC.
Protara Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Protara Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.